Acid-fast bacillus (AFB) spinal osteomyelitis in a patient with AIDS is often presumed to be caused by reactivated Mycobacterium tuberculosis. However, other AFB pathogens can mimic M. tuberculosis and, to ensure appropriate and adequate therapy, should be considered by clinicians. We present a case of aggressive spinal osteomyelitis caused by Mycobacterium heckeshornense in an AIDS patient; a review of the literature is also included.
drolysis. Despite strong biochemical similarity to Mycobacterium xenopi, the isolate grew equally well at 37°C and 42°C. The isolate was sent for molecular identification by 16S rRNA gene sequencing and identified as Mycobacterium heckeshornense; there was 100% identity with M. heckeshornense over a match length of 986 bp, while there were 30 mismatches with the next closest match, M. xenopi. The identification was performed at a large commercial reference laboratory using CLSI guidelines for percent match with the SmartGene Mycobacterium database. Drug susceptibility data using the Sensititre plate for slow-growing mycobacteria (Trek, Oakwood Village, OH), also performed by the same large commercial reference laboratory, was available at time of isolate identification (ID), showing susceptibility to isoniazid (MIC, 0.2 g/ ml), rifampin (MIC, 1.0 g/ml), ethambutol (MIC, 5.0 g/ml), and clarithromycin (MIC, 1.0 g/ml) but resistance to pyrazinamide (MIC, 100 g/ml). Interpretations were made using CLSI breakpoints. At this time, 5 weeks after antimycobacterial therapy was started, there had been remarkable clinical response with resolution of spinal pain. Due to potential drug interactions and since azithromycin had already been administered at 1,250 mg weekly, RHZE was continued through 8 weeks, with a plan to continue rifabutin and isoniazid for at least 18 months.
We report the first case of AIDS-associated M. heckeshornense spinal disease. M. heckeshornense is a nontuberculous mycobacterium (NTM) that rarely causes human disease and has also been associated with feline and porcine illness (1) (2) (3) . NTM are present in the environment, may be especially prevalent in tap water, and rarely cause osteomyelitis. M. heckeshornense is thought to be a very rare cause of bronchopulmonary disease in humans, but not osteomyelitis (3).
First described in 2000, M. heckeshornense is a scotochromogenic NTM closely related to M. xenopi that grows at 37°C, 40°C, and 45°C; biochemically, it is often heat-stable-catalase positive but negative for all other standard mycobacterial biochemical tests (4). However, our isolate was negative for heat-stable catalase activity. Very limited drug susceptibility data show that the species has variable susceptibility to first-line antituberculosis drugs (4) .
We searched the English-language literature using Pub-Med with search term "heckeshornense" and found 15 articles and 11 cases of human infection with M. heckeshornense (Table 1) . Interestingly, 55% of these patients were thought to be immunocompetent. Due to an aggressive clinical presentation, most cases were initially treated as reactivated M. tuberculosis with standard four-drug therapy, which was later modified to target M. heckeshornense. Given its close phylogenetic relationship to M. xenopi, some authors advocate treating it as such with isoniazid, rifamycin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5) . In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. Due to their variable susceptibility to first-line antituberculous drugs, M. heckeshornense isolates should be tested for drug susceptibility and this information considered when a treatment regimen is being selected (5, 6) .
Given our experience with positive and then negative M. gordonae hybridization probe results, we urge clinicians to pursue definitive methods of mycobacterial identification when the clinical syndrome is not consistent with rapid diagnostic test results. The RLU value for the M. gordonae probe was just above the assay cutoff, suggesting a possible false-positive result. The results for two repeat tests of the isolate, one from growth on an LJ slant and the other from the broth sediment, were negative. Morphologically and biochemically, M. heckeshornense resembles and may be commonly misidentified as M. xenopi in the absence of careful growth temperature studies or gene sequencing.
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